| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Director | See Remarks
3 companies
Jonathan I Lieber is Chief Financial Officer at RLYB, with reported holdings spanning 3 companies. The disclosed holdings are worth an estimated $235K at current prices.
Our model assigns Jonathan I Lieber a below-average insider score of 26/100, based on 3 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -64.6%.
Jonathan I Lieber's largest disclosed position is in RLYB as Chief Financial Officer, worth about $225K. Net of sales, the RLYB filings show accumulation of 3,612 shares.
Jonathan I Lieber has 22 Form 4 filings on record from July 2015 to October 2026, across 3 companies: Chief Financial Officer at Rallybio (RLYB), 2023–2026; Director at Decoy Therapeutics (DCOY), 2020–2026; Chief Financial Officer at Ocugen (OCGN), 2015–2018.
The 34 reported transactions were 16 option or other derivative awards, 5 dispositions back to the company, 4 option exercises and 4 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $43K and 2 sales worth about $14K.
The largest open-market purchase was 5,000 shares of RLYB at an average $5.21 on March 14, 2023, about $26K. Twelve months later RLYB was down 67%.
The largest open-market sale was 599 shares of RLYB at an average $16.04 on October 27, 2026, about $10K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | RLYB Rallybio Corporation | Chief Financial Officer | Sell | 599 | $16.04 | $9,607.96 | -3.7% | - | - | |
| Feb 23, 2026 | RLYB Rallybio Corporation | Chief Financial Officer | Sell | 789 | $5.06 | $3,992.34 | -16.1% | +167.3% | - | |
| Mar 14, 2023 | RLYB Rallybio Corp | See Remarks | Buy | 5,000 | $5.21 | $26,050.00 | New | +51.0% | -66.6% | |
| Jun 7, 2022 | DCOY Salarius Pharmaceuticals, Inc. | - | Buy | 37,500 | $0.19 | $7,016.25 | New | +7.0% | -62.5% | |
| Dec 2, 2016 | OCGN Ocugen, Inc. | Chief Financial Officer | Buy | 5,000 | $1.95 | $9,730.50 | New | - | - |